Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

ConclusionOur study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy.

Source: International Journal of Clinical Oncology - February 27, 2019 Category: Cancer & Oncology Source Type: research